Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Vascular ; 31(2): 341-349, 2023 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-34957865

RESUMO

OBJECTIVES: This thesis aims to explore the relationship between tea consumption and ankle-brachial index (ABI) and further studies the relationship between tea consumption and lower extremity atherosclerosis. METHODS: This is a cross-sectional, epidemiological survey of 17,373 subjects selected from the staff of Kailuan Group who had come to Kailuan General Hospital for a health examination from January 2016 to December 2017. Tea consumption was obtained by questionnaires. ABI was measured using an automated analyzer. The other data, such as age, gender, body mass index (BMI), and so on, was collected on the same day of the health examination results. The relationship between tea drinking habits and ABI was studied using logistic regression and multivariate linear regression analysis. RESULTS: Among the 17,373 analyzed subjects, the difference in age, gender, BMI, heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), uric acid (UA), C-reactive protein (CRP), fasting blood-glucose (Fbg), and ABI was statistically significant in the tea-drinking group and the nontea-drinking group (p < 0.05). Multiple logistic regression models revealed that tea consumption was a positive predictor for ABI (odds ratio (OR) = 0.782, confidence interval (CI), 0.615-0.994) (p < 0.05). Multivariate linear regression analysis of the ABI value showed that frequent tea-drinking has a positive correlation with the ABI value (p < 0.05). CONCLUSIONS: The higher tea consumption is significantly associated with higher ABI which means less risk for lower extremity atherosclerosis.


Assuntos
Índice Tornozelo-Braço , Aterosclerose , Humanos , Estudos Transversais , HDL-Colesterol , Chá , Fatores de Risco
2.
Acta Pharmacol Sin ; 43(2): 494-503, 2022 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-33927359

RESUMO

Furmonertinib was designed for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. In this study, we investigated the metabolic disposition and mass balance in humans and tissue distribution in rats. After a single oral administration of 97.9 µCi/81.5 mg [14C]-furmonertinib mesylate to six healthy male volunteers, the absorption process of furmonertinib was fast with a tmax of total plasma radioactivity at 0.75 h. Afterward, furmonertinib was extensively metabolized, with the parent drug and active metabolite AST5902 accounting for 1.68% and 0.97% of total radioactivity in plasma. The terminal t1/2 of total radioactivity in plasma was as long as 333 h, suggesting that the covalent binding of drug-related substances to plasma proteins was irreversible to a great extent. The most abundant metabolites identified in feces were desmethyl metabolite (AST5902), cysteine conjugate (M19), and parent drug (M0), which accounted for 6.28%, 5.52%, and 1.38% of the dose, respectively. After intragastric administration of 124 µCi/9.93 mg/kg [14C]-furmonertinib to rats, drug-related substances were widely and rapidly distributed in tissues within 4 h. The concentration of total radioactivity in the lung was 100-fold higher than that in rat plasma, which could be beneficial to the treatment of lung cancer. Mass balance in humans was achieved with 77.8% of the administered dose recovered in excretions within 35 days after administration, including 6.63% and 71.2% in urine and feces, respectively. In conclusion, [14C]-furmonertinib is completely absorbed and rapidly distributed into lung tissue, extensively metabolized in humans, presented mostly as covalent conjugates in plasma, and slowly eliminated mostly via fecal route.


Assuntos
Antineoplásicos , Adulto , Animais , Feminino , Humanos , Masculino , Ratos , Administração Oral , Antineoplásicos/sangue , Antineoplásicos/farmacocinética , Cromatografia Líquida de Alta Pressão , Receptores ErbB/antagonistas & inibidores , Ratos Sprague-Dawley , Distribuição Tecidual
3.
Invest New Drugs ; 39(4): 1011-1018, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-33506323

RESUMO

Background Alflutinib is a novel irreversible and highly selective third-generation EGFR inhibitor currently being developed for the treatment of non-small cell lung cancer patients with activating EGFR mutations and EGFR T790M drug-resistant mutation. Alflutinib is mainly metabolized via CYP3A4 to form its active metabolite AST5902. Both alflutinib and AST5902 contribute to the in vivo pharmacological activity. The aim of this study was to investigate the effects of rifampicin (a strong CYP3A4 inducer) on the pharmacokinetics of alflutinib and AST5902 in healthy volunteers, thus providing important information for drug-drug interaction evaluation and guiding clinical usage. Methods This study was designed as a single-center, open-label, and single-sequence trial over two periods. The volunteers received a single dose of 80 mg alflutinib on Day 1/22 and continuous doses of 0.6 g rifampicin on Day 15-30. Blood sampling was conducted on Day 1-10 and Day 22-31. The pharmacokinetics of alflutinib, AST5902, and the total active ingredients (alflutinib and AST5902) with or without rifampicin co-administration were respectively analyzed. Results Co-administration with rifampicin led to 86% and 60% decreases in alflutinib AUC0-∞ and Cmax, respectively, as well as 17% decrease in AST5902 AUC0-∞ and 1.09-fold increase in AST5902 Cmax. The total active ingredients (alflutinib and AST5902) exhibited 62% and 39% decreases in AUC0-∞ and Cmax, respectively. Conclusions As a strong CYP3A4 inducer, rifampicin exerted significant effects on the pharmacokinetics of alflutinib and the total active ingredients (alflutinib and AST5902). The results suggested that concomitant strong CYP3A4 inducers should be avoided during alflutinib treatment. This trial was registered at http://www.chinadrugtrials.org.cn . The registration No. is CTR20191562, and the date of registration is 2019-09-12.


Assuntos
Indutores do Citocromo P-450 CYP3A/farmacologia , Indóis/farmacocinética , Inibidores de Proteínas Quinases/farmacocinética , Piridinas/farmacocinética , Pirimidinas/farmacocinética , Rifampina/farmacologia , Adolescente , Adulto , Área Sob a Curva , Citocromo P-450 CYP3A/efeitos dos fármacos , Citocromo P-450 CYP3A/metabolismo , Interações Medicamentosas , Receptores ErbB/biossíntese , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem
4.
Plant Commun ; 2(5): 100214, 2021 09 13.
Artigo em Inglês | MEDLINE | ID: mdl-34746760

RESUMO

Sphingolipids, which comprise membrane systems together with other lipids, are ubiquitous in cellular organisms. They show a high degree of diversity across plant species and vary in their structures, properties, and functions. Benefiting from the development of lipidomic techniques, over 300 plant sphingolipids have been identified. Generally divided into free long-chain bases (LCBs), ceramides, glycosylceramides (GlcCers) and glycosyl inositol phosphoceramides (GIPCs), plant sphingolipids exhibit organized aggregation within lipid membranes to form raft domains with sterols. Accumulating evidence has revealed that sphingolipids obey certain trafficking and distribution rules and confer unique properties to membranes. Functional studies using sphingolipid biosynthetic mutants demonstrate that sphingolipids participate in plant developmental regulation, stimulus sensing, and stress responses. Here, we present an updated metabolism/degradation map and summarize the structures of plant sphingolipids, review recent progress in understanding the functions of sphingolipids in plant development and stress responses, and review sphingolipid distribution and trafficking in plant cells. We also highlight some important challenges and issues that we may face during the process of studying sphingolipids.


Assuntos
Plantas/metabolismo , Esfingolipídeos/metabolismo , Transporte Biológico
5.
Infect Dis Poverty ; 10(1): 59, 2021 Apr 29.
Artigo em Inglês | MEDLINE | ID: mdl-33926548

RESUMO

BACKGROUND: Information on the prevalence and resistance spectrum of nontuberculous mycobacteria (NTM) in China is mainly based on regional or local data. To estimate the proportion of NTM cases in China, a national survey of NTM pulmonary disease was carried out based on acid-fast positive sputum samples collected in 2013. METHODS: Sputum samples collected from enrolled presumptive cases in 72 nationwide tuberculosis surveillance sites from the 31 provinces in the mainland of China were cultured using L-J medium at the National tuberculosis reference laboratory (NTRL). MALDI-TOF MS identified the species of re-cultured strains, and minimal inhibitory concentrations (MICs) were determined to evaluate the drug susceptibility of NTM isolates. Data analysis used statistical software SPSS version 22.0 for Windows statistical package. RESULTS: Of 4917 mycobacterial isolates cultured, 6.4% [317/4917, 95% confidence interval (CI) 5.8%-7.2%] were confirmed as NTM, among which 7.7% (287/3709, 95% CI 6.9%-8.6%) were from the southern region. In inland and coastal China, 87.7% (95% CI 78.7%-93.2%) and 50.0% (95% CI 43.7%-56.3%) of isolates, respectively, were slow-growing mycobacteria (SGM), with the remaining rapid growing mycobacteria (RGM). A total of 29 species were detected, Mycobacterium abscessus had higher clarithromycin-inducible resistance rates than M. massiliense (65.67% vs 2.22%). M. kansasii presented lower resistance rates in linezolid and moxifloxacin than M. avium-intracellulare complex (3.23% vs 66.67%, 0 vs 47.22%) and other SGM (3.23% vs 38%, 0 vs 26%). CONCLUSIONS: More NTM pulmonary disease was observed in the south and coastal China (P < 0.01). SGM was widely distributed, and more RGM are present in southern and coastal China (P < 0.01). The antimicrobial resistance spectrum of different NTM species was significantly different and accurate species identification would be facilitated to NTM pulmonary disease treatment.


Assuntos
Antibacterianos , Micobactérias não Tuberculosas , Antibacterianos/farmacologia , China/epidemiologia , Farmacorresistência Bacteriana , Incidência
6.
Plant Signal Behav ; 15(12): 1833142, 2020 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-33043777

RESUMO

The plant extracellular vesicles (EVs) are lipid-enveloped nano-particles containing proteins, nucleic acids and metabolites and function in plant development and response. The Arabidopsis four transmembrane protein TETRASPANIN 8 (TET8) knock-out mutant tet8 secreted less EVs than the wild-type (WT). In this report, we show that the tet8 mutant was attenuated in the plant hormone jasmonate (JA) accumulation in response to mechanical wounding treatment. We also noticed that the EVs contained a high level of phospholipids phosphatidic acids (PAs) which may serve as precursors of JA biosynthesis during wound-triggered-self-healing processes. Thus, we propose an open question about a potential role of EVs or TET8 or both in damage-associated JA response.


Assuntos
Arabidopsis/metabolismo , Ciclopentanos/metabolismo , Vesículas Extracelulares/metabolismo , Oxilipinas/metabolismo , Folhas de Planta/metabolismo , Proteínas de Arabidopsis/genética , Proteínas de Arabidopsis/metabolismo , Vias Biossintéticas , Mutação/genética , Ácidos Fosfatídicos/metabolismo , Regeneração
7.
Mol Plant ; 13(10): 1523-1532, 2020 10 05.
Artigo em Inglês | MEDLINE | ID: mdl-32717349

RESUMO

Plant extracellular vesicles (EVs) are membrane-enclosed nanoparticles that play diverse roles in plant development and response. Recently, impressive progress has been made in the isolation and identification of the proteins and RNAs carried in plant EVs; however, the analysis of EV lipid compositions remains rudimentary. Here, we performed lipidomic analysis of Arabidopsis rosette leaf EVs, revealing a high abundance of certain groups of lipids, in particular sphingolipids, in the EVs. Remarkably, the EV sphingolipids are composed of nearly pure glycosylinositolphosphoceramides (GIPCs), which are green lineage abundant and negatively charged. We further showed that the Arabidopsis TETRASPANIN 8 (TET8) knockout mutant has a lower amount of cellular GIPCs and secrets fewer EVs, companied with impaired reactive oxygen species (ROS) burst toward stresses. Exogenous application of GIPCs promoted the secretion of EVs and ROS burst in both the WT and tet8 mutant. The characteristic enrichment of sphingolipid GIPCs provides valuable insights into the biogenesis and function of plant EVs.


Assuntos
Arabidopsis/metabolismo , Vesículas Extracelulares/metabolismo , Lipidômica/métodos , Folhas de Planta/metabolismo , Glicoesfingolipídeos/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Esfingolipídeos/metabolismo
8.
Wei Sheng Wu Xue Bao ; 46(3): 412-7, 2006 Jun.
Artigo em Chinês | MEDLINE | ID: mdl-16933611

RESUMO

In order to develop recombinant porcine interferon beta with high bioactivity, the rare codes that encoded 3th, 7th and 164th amino acids of porcine interferon beta mature protein were mutant into bias codes of Pichia pastoris and then the modified gene was introduced to yeast secreted expression vector pPICZ alphaA which resulted in pPICZalphaA-PIB. The SacI linearized plasmid pPICZalphaA-PIB was transformed into Pichia pastoris X-33 by electroporation. The transformants were identified by PCR using PoIFN-beta and AOX1 specific primers. The expression of PoIFN-beta was induced with methanol. Several positive clones were obtained and the one namely B1 produced the highest level of PoIFN-beta. The B1 was further fermented in shake-flask in larger volume. The concentration of the secreted PoIFN-beta was about 60 microg/mL and its antiviral activity is about 2.5 x 10(5) U/mL, so the specific activity of porcine interferon beta produced by the Pichia pastoris is approximately 4.17 x 10(6) U/mg. The expressed supernatant was concentrated and identified by SDS-PAGE and Western blot. There are two major proteins with respective molecular mass of approximately 25 kDa and 28 kDa in the supernatant. The results of Western blot indicated that the two proteins were positively reacted and manifested well PoIFN-beta antigenicity. In contrast with the deduced theoretical molecular mass value of PoIFN-beta, the expressed two major proteins were larger which maybe due to the difference of glycosylation. The antiviral effect of recombinant porcine interferon beta (rPoIFN-beta) on Pseudorabies virus (PrV) was studied in the present experiment. The result indicated that rPoIFN-beta could effectively inhibit the replication of PrV in MDBK cells, especially during the early phage of the virus replication.


Assuntos
Herpesvirus Suídeo 1/efeitos dos fármacos , Herpesvirus Suídeo 1/fisiologia , Interferon beta/genética , Interferon beta/farmacologia , Pichia/metabolismo , Suínos , Replicação Viral/efeitos dos fármacos , Animais , Linhagem Celular , Clonagem Molecular , Expressão Gênica , Engenharia Genética , Interferon beta/biossíntese , Interferon beta/isolamento & purificação , Pichia/genética , Análise de Sequência de DNA
9.
Int J Clin Exp Pathol ; 6(9): 1806-16, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24040445

RESUMO

Despite the recent realization of Interleukin (IL)-35 in tumorigenesis, its exact impact on colorectal cancer (CRC) progression and prognosis, however, is yet to be elucidated clearly. We thus in the present report conducted comparative analysis of IL-35 levels between CRC patients and matched control subjects. IL-35 is highly expressed in all CRC tissues, which can be detected in vast majority of colorectal cancer cells. IL-35 levels in CRC lysates and serum samples are highly correlated to the severity of malignancy and the clinical stage of tumor. Particularly, a significant reduction for serum IL-35 was noted in patients after surgical resection, indicating that IL-35 promotes CRC progression associated with poor prognosis. Mechanistic study demonstrated a significant correlation between serum IL-35 levels and the number of peripheral regulatory T (Treg) cells in CRC patients, suggesting that IL-35 implicates in CRC pathogenesis probably by inducing Treg cells, while cancer cell-derived IL-35 may also recruit Treg cells into the tumor microenvironment in favor of tumor growth. Together, our data support that IL-35 could be a valuable biomarker for assessing CRC progression and prognosis in clinical settings.


Assuntos
Biomarcadores Tumorais/metabolismo , Neoplasias Colorretais/metabolismo , Interleucinas/metabolismo , Proteínas Adaptadoras de Transdução de Sinal/metabolismo , Adulto , Idoso , Biomarcadores Tumorais/sangue , Estudos de Casos e Controles , Proteínas de Ciclo Celular/metabolismo , Quimiotaxia de Leucócito , Colectomia , Neoplasias Colorretais/sangue , Neoplasias Colorretais/imunologia , Neoplasias Colorretais/patologia , Neoplasias Colorretais/cirurgia , Progressão da Doença , Feminino , Humanos , Interleucinas/sangue , Linfócitos do Interstício Tumoral/imunologia , Linfócitos do Interstício Tumoral/metabolismo , Masculino , Pessoa de Meia-Idade , Antígenos de Histocompatibilidade Menor , Gradação de Tumores , Estadiamento de Neoplasias , Linfócitos T Reguladores/imunologia , Linfócitos T Reguladores/metabolismo , Resultado do Tratamento , Microambiente Tumoral , Adulto Jovem
10.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi ; 27(4): 419-21, 2011 Apr.
Artigo em Chinês | MEDLINE | ID: mdl-21481321

RESUMO

AIM: To prokaryotically express and purify fusion protein containing extracellular region of human BTLA and prepare the antiserum of it. METHODS: Human BTLA (hBTLA) gene was amplified by PCR, digested with enzymes, ligated and subcloned into a his-tagged prokaryotic expression vector to generate a recombinant plasmid named pET28a-hBTLA. Then pET28a-hBTLA was transformed into E.coli BL21 (DE3). The hBTLA fusion protein was obtained upon IPTG induction, purified by Ni-NTA Purification System, and analyzed by SDS-PAGE. Rabbit anti-hBTLA antiserum was prepared and identified. RESULTS: The pET28a-hBTLA plasmid was confirmed to carry the correct hBTLA gene by sequencing. It expressed a 15.7kD protein that could be purified by Ni-NTA purification system. The titer of the multiclonal antibody was 1:16 detected by double diffusion test, and 1:20 000 by ELISA, respectively. The anti-hBTLA antibodies can bind to hBTLA specifically shown by Western blot. CONCLUSION: The prokaryotic expression vector has been constructed successfully, leading to highly purified hBTLA protein. The antiserum of hBTLA has been prepared, with high titer and specificity.


Assuntos
Soros Imunes/imunologia , Receptores Imunológicos/genética , Animais , Escherichia coli/genética , Humanos , Plasmídeos , Coelhos , Receptores Imunológicos/imunologia , Proteínas Recombinantes/isolamento & purificação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA